Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma
11 déc. 2022 10h00 HE
|
Harpoon Therapeutics
Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed...
CURE Media Group announces D.L. Hughley as keynote panel moderator for the 2022 Multiple Myeloma Heroes and Health Equity Heroes awards
05 déc. 2022 13h38 HE
|
CURE Media Group
CRANBURY, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
01 déc. 2022 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced it has been selected as a winner of the 2022 Amazon Web Services (AWS) IMAGINE...
CURE Media Group announces 2022 Multiple Myeloma Heroes®
17 nov. 2022 09h00 HE
|
CURE Media Group
CRANBURY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
Scip & Savor for a Cure Fundraiser Benefits the International Myeloma Foundation (IMF) and Family Reach
27 oct. 2022 08h45 HE
|
International Myeloma Foundation
STUDIO CITY, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) today announced the details of the recent fundraising celebration hosted by Fatima Scipione and her...
The Annual Miracles for Myeloma 5K Hybrid Run/Walk Celebrates 10th Anniversary
29 sept. 2022 08h45 HE
|
International Myeloma Foundation
CLARK, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- The Annual Miracles for Myeloma 5K Hybrid Run/Walk will be celebrating its tenth anniversary this year. For the past nine years, this annual event has...
CURE Media Group Opens Nominations for Multiple Myeloma Heroes® Award Program
04 août 2022 15h54 HE
|
CURE Media Group
The Recognition Will Honor Individuals Who Have Made a Significant Difference in the Lives of Those Affected by Multiple Myeloma CRANBURY, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- CURE Media...
Moving Mountains for Multiple Myeloma® Tackles Mt. Washington
01 juil. 2022 09h03 HE
|
CURE Media Group
CRANBURY, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- Moving Mountains for Multiple Myeloma®, a program with the mission of raising funds and awareness for multiple myeloma research, will take the...
CORRECTION - Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 18h12 HE
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, May 05, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Celyad Oncology SA (Euronext & Nasdaq: CYAD), please note that in the...
Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights
05 mai 2022 16h05 HE
|
Celyad Oncology SA
Enrollment continues in Phase 1 dose-escalation IMMUNICY-1 trial for lead shRNA-based allogeneic CAR T candidate, CYAD-211, for relapsed/refractory multiple myeloma (r/r MM)Dialogue continues with...